Q4 2024 Earnings Call Transcript February 28, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

Proficio Capital Partners LLC bought a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the ...

Discover the top 5 undervalued Health Care Providers & Services stocks for Wednesday, March 12 based on AAII’s Stock Grades.

UBS analyst Dan Leonard lowered the firm’s price target on Fulgent Genetics (FLGT) to $20 from $27 and keeps a Neutral rating on the shares.

StockNews.com upgraded shares of Fulgent Genetics (NASDAQ:FLGT – Free Report) from a sell rating to a hold rating in a research report released on Wednesday. Separately, Piper Sandler decreased their ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Fulgent Genetics (FLGT) to $16 from $22 following quarterly results.

Full Year 2024 Results Key Financial Results Revenue: US$283.5m (down 2.0% from ...

FULGENT GENETICS ($FLGT) posted quarterly earnings results on Friday, February 28th. The company reported earnings of $0.04 per share, beating estimates of -$0.13 by ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business a ...

Greetings and welcome to the Fulgent Genetics Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode. [Operator Instructions]. A question-and-answer session ...

Fulgent Genetics specializes in laboratory services and therapeutic development. Its laboratory division provides anatomic pathology and precision diagnostic testing through certified laboratories ...